Prednisone is NOT Recommended for Plaque Psoriasis
Prednisone should not be used for the treatment of plaque psoriasis. While the FDA label provides general dosing guidance for prednisone (5-60 mg per day depending on disease entity) 1, there is no specific indication or dosing recommendation for plaque psoriasis, and current dermatology guidelines do not support its use for this condition.
Why Prednisone is Avoided in Plaque Psoriasis
The major concern with systemic corticosteroids in psoriasis is the risk of severe disease rebound and potential transformation to pustular psoriasis upon withdrawal. This has been a long-standing principle in dermatology practice, making systemic corticosteroids contraindicated as monotherapy for plaque psoriasis.
The one exception noted in the literature involves psoriatic arthritis (not plaque psoriasis alone), where low-dose prednisone (10 mg on alternate days, tapered to 2.5 mg on alternate days) was used successfully in combination with methotrexate for severe joint disease 2. However, this was specifically for arthritis management, not for skin disease.
Recommended Systemic Treatments for Plaque Psoriasis
According to current guidelines, the appropriate systemic treatments for moderate-to-severe plaque psoriasis include 3, 4:
First-Line Systemic Options:
Cyclosporine:
- Dosing: 2.5-5.0 mg/kg/day in two divided doses
- Duration: 12-16 weeks for induction
- Achieves PASI 75 in 50-97% at 5 mg/kg/day and 28-85% at 2.5 mg/kg/day
- Best used as short-term interventional therapy due to toxicity concerns with long-term use 3, 4
Acitretin:
- Dosing: 20-70 mg/day (dose-dependent efficacy)
- 23% achieve PASI 75 at 50 mg/day over 8 weeks
- May be used for maintenance therapy 4
Methotrexate:
- Standard DMARD for psoriasis
- Often combined with other agents 2
Most Effective Biologic Options:
Based on the most recent network meta-analysis, the highest-ranked treatments for achieving PASI 90 are 5, 6:
- Infliximab (moderate-certainty evidence)
- Bimekizumab (high-certainty evidence)
- Ixekizumab (moderate-certainty evidence)
- Risankizumab (moderate-certainty evidence)
These anti-IL17 and anti-IL23 biologics demonstrate superior efficacy compared to older systemic agents and have similar clinical effectiveness when compared against each other.
Critical Clinical Pitfall
Never use systemic corticosteroids as monotherapy for plaque psoriasis. The risk of disease flare upon discontinuation outweighs any short-term benefit. If a patient presents on prednisone for psoriasis, transition them to appropriate disease-modifying therapy (cyclosporine, biologics, or other guideline-recommended agents) while tapering the steroid gradually to avoid rebound.